SCHEMBL14909626

SCHEMBL14909626

CC(C)(C)OC(=O)N[C@@H]1CCN(C(=O)OCc2ccccc2)C[C@@H]1N

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CTSK P43235 1/20 0.44
HSD11B1 P28845 1/20 0.44
GRIN2B Q13224 2/20 0.44
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
GPR119 Q8TDV5 1/20 0.43
STS P08842 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
PARP1 P09874 1/20 0.43
SYK P43405 1/20 0.43
CPB1 P15086 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21312054 1.00 PDE4B (0.53) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL14928609 1.00 PDE4B (0.53) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL21306738 1.00 PDE4B (0.53) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL21312266 1.00 PDE4B (0.53) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL14909624 1.00 PDE4B (0.53) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL14911483 0.93 PDE4B (0.56) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL16164661 0.93 PDE4B (0.56) PDE4BSMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL5435529 0.92 HSD11B1 (0.48) SMN1; SMN2NPC1RAB9AHTTL3MBTL1
SCHEMBL2845311 0.92 HSD11B1 (0.48) SMN1; SMN2NPC1RAB9AHTTL3MBTL1
SCHEMBL16667924 0.92 HSD11B1 (0.48) SMN1; SMN2NPC1RAB9AHTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK PDE4B 1256/4885SMN1; SMN2 2190/4885NPC1 1367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.